Posted by Michael Wonder on 09 Jul 2018
PAH patients in England denied access to Actelion’s Uptravi on NHS
9 July 2018 - Actelion’s Uptravi will not be funded on the NHS for patients with pulmonary arterial hypertension, after the drug failed to make it into NHS England’s latest round of specialised commissioning approvals.
The drug maker has slammed the decision, which it argues will delay access to Uptravi (selexipag) as a combination treatment for pulmomary arterial hypertension in adult patients with one of the more severe forms of the disease who are insufficiently controlled on oral treatment.
“This ruling will create a disparity in access to selexipag throughout the UK, with patients in Scotland and Wales already having access,” it stressed.
